ASPEN PHARMACARE HOLDINGS LIMITED - Aspen Pre-Close Statement Clarification
14 December 2018 10:03
APN 201812140027A
Aspen Pre-Close Statement – Clarification

(Incorporated in the Republic of South Africa) ("Aspen Holdings")
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively "Aspen" or "the Group")


Based upon enquiries received since issuing the Pre-Close Statement released on SENS after
market close yesterday, 13 December 2018, Aspen wishes to clarify that agreement was reached
with Aspen’s syndicate of funders during the period to November 2018, providing multi-currency
facilities to negotiate a conditional and temporary adjustment to Aspen’s leverage ratio covenant
as at 31 December 2018 as reported in yesterday’s SENS.

14 December 2018

Investec Bank Limited

About Aspen

Aspen is a leading global player in specialty, branded and generic pharmaceuticals with an extensive basket
of products that provide treatment for a broad spectrum of acute and chronic conditions experienced
through all stages of life. Aspen continues to increase the number of lives benefitting from its products,
reaching more than 150 countries.

Aspen has a strong presence in both emerging and developed countries. Its emerging market footprint
includes Sub-Saharan Africa, Latin America, South East Asia, China, Eastern Europe and the Commonwealth
of Independent States, comprising Russia and the former Soviet Republics. From a developed world
perspective Aspen is one of the leading pharmaceutical companies in Australia and has a growing presence
in other developed countries, most notably in Western Europe.

Aspen operates with an established business presence in approximately 50 countries spanning 6 continents
and employs more than 10,000 people. The Group operates 25 manufacturing facilities across 18 sites.
Aspen holds international manufacturing approvals from some of the most stringent global regulatory
agencies including the FDA, TGA and EMA. Aspen’s manufacturing capabilities are scalable to demand and
cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs
and infant nutritionals.

Aspen is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks
amongst the top 40 listed companies on this exchange. For more information visit:

Date: 14/12/2018 10:03:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.